Aberdeen Group plc Has $13.56 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Aberdeen Group plc increased its holdings in Xenon Pharmaceuticals Inc. by 42.4%, now owning 404,154 shares worth approximately $13.56 million.
• A variety of analysts have recently adjusted their price targets and ratings for the stock, with estimates ranging from a low of $47.00 to a high of $55.00 and an average rating of "Moderate Buy".
• Xenon Pharmaceuticals reported an EPS of ($1.07) for the last quarter, missing the consensus estimate of ($1.03), while its stock opened at $37.82 with a market cap of $2.92 billion.

Aberdeen Group plc lifted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 42.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 404,154 shares of the biopharmaceutical company's stock after buying an additional 120,255 shares during the quarter. Aberdeen Group plc owned about 0.53% of Xenon Pharmaceuticals worth $13,559,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in XENE. Geode Capital Management LLC grew its stake in shares of Xenon Pharmaceuticals by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock valued at $2,726,000 after buying an additional 720 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at $797,000. Barclays PLC grew its stake in shares of Xenon Pharmaceuticals by 20.9% in the fourth quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 3,134 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at $316,000. Finally, J. Safra Sarasin Holding AG bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at $697,000. 95.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on XENE. Wall Street Zen cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. Wedbush lifted their price objective on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 12th. Needham & Company LLC reduced their price objective on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, Royal Bank Of Canada reduced their price objective on shares of Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Eleven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Buy" and an average price target of $53.20.

Xenon Pharmaceuticals Stock Up 1.7%

Shares of Xenon Pharmaceuticals stock traded up $0.66 during trading on Friday, reaching $38.84. The company's stock had a trading volume of 1,186,173 shares, compared to its average volume of 1,069,916. The business's 50-day moving average price is $33.16 and its 200-day moving average price is $33.91. The firm has a market cap of $2.99 billion, a PE ratio of -10.94 and a beta of 1.16. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same quarter in the prior year, the company earned ($0.75) EPS. Equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.